Table 3 Comparison of patient characteristics between CD8 + T-cell high and CD8 + T-cell low. The data is.
CD 8 + T-cell high (n = 18) | CD 8 + T-cell low (n = 19) | p-value | |
|---|---|---|---|
Age (median, IQR) | 54y (41.25y – 64.75y) | 56y (46y – 63y) | 0.48 |
Histological subtype | |||
Signet cell differentiation | 5 (27.8%) | 1 (5.3%) | 0.09 |
PCI (median, IQR) | 8 (4.5–13) | 7.5 (5–16.25) | 0.74 |
PM occurence | 10 (55.6% synchronous) | 13 (68.4%) synchronous | 0.50 |
8 (44.4%) metachronous | 6 (31.6%) metachronous | ||
Hematogenous metastasis | 7 (38.9%) | 12 (63.2%) | 0.19 |
(liver and lung) | |||
RAS mutations | 0.49 0.52 | ||
KRAS mutation | 7 (38.9%) | 9 (47.4%) | |
NRAS mutation | 2 (11.1%) | 1 (5.3%) | |
No systemic chemotherapy prior CRS/HIPEC | 4 (44.4%) | 1 (10%) | 0.40 |
Neoadjuvant chemotherapy | 4 (22.2%) | 2 (10.5%) | |
Douplet drug combination | 10 (55.6%) | 14 (73.7%) | |
Triplet drug combination | 4 (22.2) | 4 (15.8) | |
Adjuvant/additive chemotherapy | |||
First line | 16 (88.8%) | 16 (84.2%) | 0.66 |
Single drug | 2 (11.1%) | 4 (21.2%) | |
Douplet drug combination | 13 (72.2%) | 10 (52.6%) | |
+ VEGF antagonist | 5 (27.7%) | 6 (31.6%) | |
+ EGFR antagonist | 2 (11.1%) | 3 (15.8%) | |
Triplet drug combination | 1 (5.6%) | ||
+ VEGF antagonist | 1 (5.6%) | 1 (5.6%) | |
No of cycles (median, IQR) | 6 (5.5–10) | 4.5 (3–11) | |
